Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect

Razan Sakran, PharmD, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel

Avraham Frisch, MD, Department of Hematology, Rambam Health Care Campus, Haifa, Israel

Adi Elias, MD, Department of Internal Medicine, Rambam Health Care Campus, Haifa, Israel

Hend Sliman, MD, Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel

Hanna Ammuri, MD, Medical Intensive Care Unit, Rambam Health Care Campus, Haifa, Israel

Daniel Kurnik, MD, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel, and Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

Address correspondence to Dr. Sakran (r_sakran@rambam.health.gov.il).

© American Society of Health-System Pharmacists 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Purpose. To report a case of ribavirin-associated severe hyperuricemia in an immunocompromised patient treated for respiratory syncytial virus (RSV) infection.

Summary. A 21-year-old male with a past medical history of B-cell acute lymphoblastic leukemia was in full remission after allogenic bone marrow transplantation complicated with chronic graft-versus-host disease. He was hospitalized due to fever, malaise, and respiratory syndromes. A diagnosis of RSV upper respiratory tract infection complicated by secondary pneumonia was made, and oral ribavirin (600 mg in 3 divided doses daily) and intravenous levofloxacin (750 mg once daily) were initiated. On day 2 of the hospital admission, the patient’s uric acid levels had increased from a baseline of 4 to 6 mg/dL to values of 19.3 and 22.2 mg/dL after the fourth and fifth doses of ribavirin, respectively, and his serum creatinine steadily had increased from a baseline of 0.7 to 0.8 mg/dL to a value of 1.6 mg/dL. Ribavirin was discontinued after the sixth dose, and a single dose of intravenous rasburicase (7.5 mg) was administered. On day 3, the patient’s serum uric and creatinine concentrations had decreased to 4.7 mg/dL and 1.1 mg/dL, respectively. He continued to recover on antibiotics and was discharged with normal uric acid and serum creatinine levels.

Conclusion. We report a case of severe hyperuricemia and acute kidney injury that developed early after initiation of ribavirin for RSV infection and suspected bacterial pneumonia in an immunocompromised patient without hepatitis C, requiring ribavirin discontinuation and rasburicase administration. To our knowledge, this is the first reported case of severe hyperuricemia in a patient treated with ribavirin for RSV infection rather than chronic hepatitis C. Clinicians should be aware of the possibility of acute and severe hyperuricemia following ribavirin administration.

Keywords: Am J Health-Syst Pharm. 2021;78:xxx-xxx
Medication use is an important cause of hyperuricemia. While the exact incidence of drug-induced hyperuricemia is unknown, diuretics are probably the most common cause seen in clinical practice. Other medications commonly implicated include antitubercular drugs, low-dose aspirin, cytotoxic chemotherapy, calcineurin inhibitors, and nicotinic acid. Various mechanisms have been suggested, including increased uric acid reabsorption and/or decreased uric acid excretion in the renal tubuli, massive disruption of tumor cells (tumor lysis syndrome), and increased uric acid production. Drug-induced hyperuricemia is usually fully reversible upon discontinuation of the offending agent but may result in kidney injury and other manifestations of gout if not recognized and appropriately managed.

Hyperuricemia has been described as an adverse effect of ribavirin most commonly reported with use of the drug in combination with pegylated interferon-α2a/b for the treatment of chronic hepatitis C. The precise culprit—whether it be ribavirin, interferon, a drug-disease interaction, or a combination thereof—and the mechanism of this adverse effect are unclear. Here we report a case of severe ribavirin-induced hyperuricemia associated with acute kidney injury in an immunocompromised patient treated for suspected respiratory syncytial virus (RSV) airway infection, requiring ribavirin discontinuation and rasburicase administration. To our knowledge, this is the first case report to describe severe ribavirin-associated hyperuricemia in a patient receiving ribavirin outside the context of chronic hepatitis C.

To gain further insights on this apparently underrecognized adverse effect of ribavirin, we conducted a systematic literature review using PubMed and adverse drug reaction databases. PubMed was searched for articles published from database inception until April 7, 2020, without language restrictions, using the search terms ribavirin,
hyperuricemia, uric acid, and urate nephropathy. We also conducted an advanced search using the MeSH term “ribavirin” in conjunction with “hyperuricemia,” “uric acid,” or “urate nephropathy.” Moreover, a random search using these terms was conducted. Additionally, we searched adverse drug reaction databases such as EudraVigilance (the European database of suspected adverse drug reaction reports), VigiAccess (the World Health Organization’s global pharmacovigilance database), and the Canada Vigilance Adverse Reaction online database using the terms hyperuricemia, uric acid, and nephropathy.

Case report

A year prior to admission to our institution for treatment of suspected RSV infection, a 21-year-old Arab male patient had undergone allogenic bone marrow transplantation for Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia and subsequently developed chronic graft-versus-host disease. Two and a half months prior to admission to our facility, he was in full molecular remission. On the day before his hospitalization, he had contacted his hematologist after developing fever and malaise, rhinorrhea, dry cough, and dyspnea and was referred for hospitalization.

On admission, the patient’s chronic oral medication regimen included cyclosporine (25 mg/d), prednisone (5 mg/d), voriconazole (600 mg/d), acyclovir (1,200 mg/d), sulfamethoxazole/trimethoprim (960 mg twice weekly), ursodeoxycholic acid (900 mg/d), ramipril (5 mg/d), bisoprolol (10 mg/d), esomeprazole (40 mg/d), calcium carbonate (600 mg/d), and vitamin D (800 units/d). His vital signs were normal. He was of normal body size (height, 178 cm; weight, 76 kg; body mass index, 24.0 kg/m$^2$). His physical examination was unremarkable, and laboratory test results revealed macrocytic anemia (hemoglobin concentration, 11.1 g/dL) and a normal white blood cell count. A chest x-ray revealed
peribronchial cuffing but no infiltrates. A nasal swab for respiratory viruses tested positive for RSV via real-time polymerase chain reaction assay.

A diagnosis of RSV upper respiratory tract infection was made, and the immunocompromised patient was started on oral ribavirin (600 mg in 3 divided doses daily). On hospital day 2, he developed shortness of breath and pleuritic chest pain. His vital signs were notable for tachycardia (130 beats/min) and hypoxia (86% oxygen saturation when breathing room air). Computed tomography and angiography of the chest revealed bilateral perihilar infiltrations and left lower lobe consolidation compatible with lobar pneumonia, with no evidence of pulmonary emboli. He received oxygen supplementation via a high-flow nasal cannula, and intravenous levofloxacin (750 mg once daily) was started. Laboratory results revealed an increase in uric acid levels from baseline values of 4 to 6 mg/dL to values of 19.3 mg/dL after dose 4 and 22.2 mg/dL after dose 5 of ribavirin, and the serum creatinine concentration steadily increased from a baseline concentrations of 0.7 to 0.8 mg/dL to a value of 1.6 mg/dL. His hemoglobin concentration decreased from 11.1 g/dL to 10.3 g/dL. Ribavirin was discontinued after the sixth dose, and a single dose of intravenous rasburicase (7.5 mg) was administered after excluding glucose-6-phosphate dehydrogenase (G6PD) deficiency. On hospital day 2 the patient also developed moderate leukopenia (white blood cell count, 1,600-2,000 cells/µL; neutrophil count, 970-1,140 cells/µL). Later during the day, his blood pressure decreased temporarily from 110/70 to 95/50 mmHg but quickly rebounded with fluid therapy. Levofloxacin was discontinued, and vancomycin and piperacillin/tazobactam were initiated. Bronchoscopy was deferred due to impending respiratory failure.

On hospital day 3, the patient’s condition improved significantly. His hypoxia resolved with only minimal oxygen supplementation. His serum uric acid concentration
decreased to 4.7 mg/dL, his serum creatinine concentration decreased to 1.1 mg/dL, and both values continued to improve on the following day (uric acid, 3.5 mg/dL; creatinine, 0.8 mg/dL) and remained stable during the rest of the hospitalization. The patient continued to quickly recover with antibiotic therapy, and therefore resumption of RSV-directed therapy was considered unnecessary. He was discharged 9 days after admission with normal uric acid and serum creatinine levels.

Discussion

Drug-induced hyperuricemia and its potential clinical sequelae (eg, gout, kidney injury) collectively constitute an adverse drug effect that is often overlooked in clinical practice. While in most patients the magnitude of drug-induced hyperuricemia is mild and of limited clinical consequence, there is great variability in treatment response and some patients develop significant uric acid increases associated with acute or chronic uric acid nephropathy, nephrolithiasis, and gout. Mechanisms of drug-induced hyperuricemia include uric acid overproduction and/or a reduction in renal uric acid excretion.\textsuperscript{1,2}

Use of thiazides and loop diuretics is one of the most common causes of secondary hyperuricemia. They decrease renal uric acid clearance by reducing tubular secretion and increasing reabsorption.\textsuperscript{1,2} Diuretic-induced hyperuricemia appears to be dose dependent, manifests within a few days of treatment initiation, and persists during continued administration.\textsuperscript{10} The median increase of uric acid is small (about 1.0 mg/dL with use of thiazide diuretics),\textsuperscript{11} but increases may range from 6% to 35% of baseline values.\textsuperscript{3,12} Diuretic-induced hyperuricemia is reversible after discontinuation of the offending agent.\textsuperscript{1,3,12}
All reported cases of ribavirin-associated hyperuricemia occurred in patients with hepatitis C receiving combination therapy with other antiviral agents, most commonly pegylated interferon-α2 (with or without telaprevir) and sofosbuvir. Significant hyperuricemia associated with use of ribavirin in combination with pegylated interferon-α2 has been described in a number of case reports, case series, and cohort studies (summarized in Table 1). In a case series reported by Yamashita et al, among 50 patients use of pegylated interferon-α2b plus ribavirin was associated with a mild but statistically significant rise in the mean (SD) uric acid concentration, from 5.4 (1.2) mg/dL at baseline to 5.8 (1.6) mg/dL during combination therapy ($P = 0.0023$ for paired comparison), and the concentrations remained within the normal range in 85% of the patients. Interestingly, urinary uric acid excretion was increased after initiation of combination therapy with ribavirin and pegylated interferon-α2b, suggesting increased uric acid synthesis rather than reduced renal excretion as the mechanism of hyperuricemia. Moreover, the rise in uric acid was not associated with markers of hemolysis (a rise in lactate dehydrogenase [LDH] or a decline in hemoglobin), suggesting that other mechanisms contributed to ribavirin-induced hyperuricemia.

Our patient developed severe hyperuricemia and acute kidney injury within 24 hours after the initiation of ribavirin monotherapy. The early onset and the magnitude of the uric acid elevation were different from those observed with use of diuretics or in most patients treated with ribavirin and interferon combination therapy, but a case of early-onset hyperuricemia of a similar magnitude was previously described in association with ribavirin and pegylated interferon combination therapy.

The probability of a causal relationship between ribavirin therapy and hyperuricemia in our patient is high. Using the validated adverse drug reaction probability scale of Naranjo
et al,\textsuperscript{15} we determined that causality between ribavirin use and development of severe hyperuricemia can be considered probable (a cumulative score of 7) on account of previous reports of this reaction (+1), timing (+2), improvement after drug discontinuation (+1), the lack of an alternative explanation (+2), and the objective assessment of the adverse event (+1). The patient had no history of hyperuricemia, his electronic medical record revealed normal uric acid levels in recent laboratory examinations, and he had no chronic disease predisposing to hyperuricemia, such as obesity, impaired glucose tolerance and/or insulin resistance, alcohol abuse, or renal disease. The rapid and extreme rise in uric acid levels and rapid reversal after the administration of rasburicase and discontinuation of ribavirin strengthen a causal association. There was no reasonable alternative explanation for the extreme rise in uric acid. Cyclosporine use is associated with hyperuricemia in 30\% to 85\% of renal transplant recipients, probably occurring through an increase in proximal tubule uric acid reabsorption and a reduction in glomerular filtration rate secondary to afferent arteriolar vasoconstriction.\textsuperscript{1} However, cyclosporine-induced hyperuricemia was unlikely in the case reported here, as the patient had normal uric acid levels for months while on a long-term cyclosporine regimen and cyclosporine trough levels were in the low-normal range (84 ng/mL) during a hospitalization about 1 year previously.

Approximately 30\% of uric acid is eliminated via the biliary and gastrointestinal tract and the remaining 70\% through the kidneys; thus, acute kidney injury may induce hyperuricemia.\textsuperscript{16} However, this is an unlikely explanation for development of hyperuricemia in our patient, since (1) he had developed acute kidney injury previously without a significant elevation in uric acid levels; and (2) his mild acute kidney injury was unlikely to have increased uric acid concentrations to the magnitude observed. Thus, while reasons for the acute kidney injury were most likely multifactorial, including sepsis and acute uric acid
nephropathy, it is unlikely that the extreme rise in uric acid levels can be fully explained by acute kidney injury.

The underlying mechanism of ribavirin-associated hyperuricemia is unclear. One of the proposed mechanisms is the induction of dose-dependent hemolytic anemia.\textsuperscript{6,17} Ribavirin is transported into erythrocytes by the nucleoside transporter and is converted into ribavirin mono-, di-, and triphosphate derivatives. These ribavirin phosphates accumulate intracellularly because erythrocytes lack the phosphatase needed to hydrolyze them, resulting in cellular toxicity and subsequent hemolysis.\textsuperscript{18} In our patient, there was a mild decline in hemoglobin (about 1 g/dL) on the day of the marked increase in uric acid, 2 days after initiation of ribavirin, but no concomitant increase in indirect bilirubin, LDH, or aspartate transaminase. We therefore believe that hemolysis cannot fully explain the patient’s hyperuricemia. Moreover, the occurrence of ribavirin-associated hyperuricemia in the absence of significant hemolysis has been described in the literature, suggesting that additional mechanisms may exist.

Ribavirin, a guanosine analogue, inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme in the de novo synthesis pathway of guanosine triphosphate (GTP) from inosine monophosphate. GTP is required for viral replication. Inhibition of the IMPDH pathway by ribavirin may result in the increased transformation of IMP to hypoxanthine and xanthine, precursors of uric acid. Thus, ribavirin could directly increase serum uric acid synthesis through the hypoxanthine/xanthine pathway.\textsuperscript{18,19} Interestingly, hyperuricemia is also a common adverse effect of mizoribine,\textsuperscript{20-22} an immunosuppressive drug and competitive inhibitor of IMPDH\textsuperscript{23} with structural similarity to ribavirin. In fact, severe hyperuricemia (a rise in the uric acid concentration of 10.7-21.2 mg/dL) has been reported after mizoribine monotherapy.\textsuperscript{20}
We do not know why the rise in uric acid was so extreme in our patient. We hypothesize that he could carry genetic polymorphisms in genes affecting the pharmacokinetic or pharmacodynamic pathways of ribavirin. Single nucleotide polymorphisms in candidate genes thought to be involved in ribavirin pharmacokinetics have been associated with high plasma ribavirin trough concentrations.\textsuperscript{24,25} Similarly, hypofunctional polymorphisms in the genes encoding IMPDH have been described.\textsuperscript{26} Thus, it is possible that genetic variants in these pathways, while not associated with hyperuricemia at baseline, could lead to an extreme rise in uric acid when ribavirin blocks compensatory mechanisms, thereby explaining the extreme response in our patient.

If resumption of RSV-directed therapy had been required in our patient, in view of the severe adverse event related with probable causality to oral ribavirin use, we believe that a rechallenge with oral ribavirin would not have been adequate. However, we would have considered administering aerosolized ribavirin by inhalation, which has been reported to result in 500- to 1,000-fold higher peak concentrations in respiratory secretions versus plasma.\textsuperscript{27} Assuming that ribavirin-associated hyperuricemia is exposure dependent, we therefore believe that a rechallenge with aerosolized ribavirin would have been feasible. Alternatively, other RSV-directed therapies, such as palivizumab or intravenous immune globulin, could have been considered.

Conclusion

To the best of our knowledge, this is the first reported case of severe hyperuricemia appearing early after initiation of ribavirin in a patient without hepatitis C being treated for RSV infection. The acute and severe hyperuricemia was associated with acute kidney injury.
and required ribavirin discontinuation and rasburicase administration. Clinicians should be aware of the possibility of acute and severe hyperuricemia shortly after ribavirin initiation.

**Disclosures**

The authors have declared no potential conflicts of interest.
References

1. Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. *Rheumatology (Oxford).* 2017;56(5):679-688.

2. Moriwaki Y. Effects on uric acid metabolism of the drugs except the antihyperuricemics. *J Bioequivalence Bioavailab.* 2014;6(1):10-17.

3. Gelber AC, Young JH, Alonso A. Diuretic use, increased serum urate and the risk of incident gout in a population-based study of hypertensive adults: the Atherosclerosis Risk in Communities cohort study. *Arthritis Rheum.* 2013;64(1):121-129.

4. Fontana RJ. Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C. *Dig Dis Sci.* 2001;46(4):920-924.

5. Yamashita N, Enjoji M, Kotoh K, et al. Investigation of hyperuricemia during pegylated-interferon-α2b plus ribavirin combination therapy in patients with chronic hepatitis C. *J Dig Dis.* 2008;9(1):27-31.

6. Davis GL, Esteban-Mur R, Rustgi V, et al; for International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. *N Engl J Med.* 1998;339(21):1493-1499.

7. Moreno-Monteagudo JA, Fernández-Bermejo M, García-Buey L, et al. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapses to interferon monotherapy. *Aliment Pharmacol Ther.* 1998;12(8):717-723.

8. Knorr JP, Chewaproug D, Neeli S, Torres E, Zaki R. Severe interferon/ribavirin-induced hyperuricemia and urate nephropathy requiring rasburicase and hemodialysis in a liver transplant recipient. *Exp Clin Transplant.* 2015;13(6):596-599.

9. Sangrador Pelluz C, Maiques Llàcer FJ, Soler Company E. Seguridad en la práctica clínica de la triple terapia con telaprevir en la hepatitis C crónica. *Farm Hosp.*
10. Reyes AJ. Cardiovascular drugs and serum uric acid. *Cardiovasc Drugs Ther.* 2003;17(5-6):397-414.

11. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). *J Hypertens.* 2000;18(8):1149-1154.

12. Sica DA. Diuretic-related side effects: development and treatment. *J Clin Hypertens (Greenwich).* 2004;6(9):532-540.

13. Sato K, Naganuma A, Nagashima T, et al. Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. *Hepatol Res.* 2018;48(3):E347-E353.

14. Kumada H, Mochida S, Nakamuta M, et al. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression. *Hepatol Res.* 2018;48(2):184-192.

15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther.* 1981;30(2):239-245.

16. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. *Am J Kidney Dis.* 1998;32(6):917-933.

17. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet.* 1998;352(9138):1426-1432.

18. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. *J Antimicrob Chemother.* 2006;57(1):8-13.
19. Halai A, Lake-Bakaar G V. Hyperuricemia associated with ribavirin treatment of chronic hepatitis C indicating IMPDH inhibition: a possible mode of antiviral activity? 
Gastroenterology. 2000;118(4):A1445.

20. Akioka K, Ishikawa T, Osaka M, et al. Hyperuricemia and acute renal failure in renal transplant recipients treated with high-dose mizoribine. Transplant Proc. 2017;49(1):73-77.

21. Ushigome H, Uchida K, Nishimura K, et al. Efficacy and safety of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplantation: a Japanese multicenter study. Transplant Proc. 2016;48(3):794-798.

22. Yoshioka K, Ohashi Y, Sakai T, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58(1):317-324.

23. Mitchell BS, Dayton JS, Turka LA, Thompson CB. IMP dehydrogenase Inhibitors as Immunomodulators. Ann N Y Acad Sci. 1993;685:217-224.

24. Allegra S, Cusato J, De Nicolò A, et al. Role of pharmacogenetics in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomed Pharmacother. 2015;69:47-55.

25. Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother. 2020;121:109657.

26. Wu TY, Peng Y, Pellemounter LL, et al. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. Br J Pharmacol. 2010;161(7):1584-1598.
Figure 1. The patient’s serum uric acid and creatinine concentrations before and after the initiation and discontinuation of ribavirin therapy and administration of rasburicase.

**Key Points**

- Ribavirin and interferon combination therapy in patients with hepatitis C has been associated with mild increases in uric acid, and the relative contribution of each medication is unclear.
- An immunocompromised patient treated with oral ribavirin for respiratory syncytial virus infection developed a rapid-onset and extreme increase in serum uric acid concentrations associated with acute kidney injury requiring rasburicase administration.
- Clinicians should be aware of this rare adverse effect, which may also occur during ribavirin monotherapy in patients without hepatitis C.
Table 1. Summary of Evidence on Ribavirin-Associated Hyperuricemia From Literature Review

| Authors (Year Published)          | Study Design          | Antiviral Medications | Oral Ribavirin Daily Dose, mg/d | Serum Uric Acid (Baseline/Max), mg/dL | Time to Max Uric Acid Level | Main Findings                                                                 | Intervention |
|-----------------------------------|-----------------------|-----------------------|---------------------------------|--------------------------------------|-----------------------------|--------------------------------------------------------------------------------|--------------|
| Kumada et al (2014)               | Randomized control trial (n = 60) | Group A: telaprevir + INFβ + ribavirin | Weight-based dosing<sup>a</sup> | Not stated                          | Not stated                  | 20.5% of patients in group A had hyperuricemia vs 3.3% in group B              | None         |
| Davis et al (1998)<sup>5</sup>    | Randomized control trial (n = 173) | Peg-IFNα2b + ribavirin | 1,000-1,200                      | Not stated                          | Not stated                  | 42 of 173 patients (24%) had high serum uric acid levels                     | None         |
| Sangrador Pelluz et al (2013)<sup>5</sup> | Retrospective observational (n = 88) | Peg-IFNα2b + ribavirin + telaprevir | Not stated                       | Median (IQR), 57 (16-82) days       | 50% of patients had hyperuricemia                                            | None         |
| Moreno-Monteagudo et al (1998)<sup>7</sup> | Prospective cohort (n = 60) | Peg-IFNα2b + ribavirin | 1,000-1,200                      | Not stated                          | Within 1st month            | 5 of 60 patients (8.3%) had hyperuricemia                                      | None         |
| Sato et al (2018)<sup>13</sup>    | Prospective cohort (n = 142, 50 with uric acid data) | Sofosbuvir + ribavirin | Weight-based dosing<sup>a</sup> | Median, 5.6/7.5                      | Within 1st week             | 8 of 50 patients (16%) presented with hyperuricemia                           | 6% of patients received febuxostat |
| Yamashita et al (2008)<sup>5</sup> | Case series (n = 50) | Peg-IFNα2b with or without ribavirin | 100-800                          | Mean (SD), 5.4 (1.2)/5.8 (1.6)       | Not stated                  | Mild but statistically significant rise in uric acid                          | None         |
| Knorr et al (2015)<sup>5</sup>    | Case report            | Peg-IFNα2b + ribavirin | 400                              | Not stated/23.4                     | 72 hours                    | Severe hyperuricemia and urate nephropathy                                    | Discontinuation of ribavirin and Peg-IFNα2b, |
Weight-based dosing was as follows: weight of ≤60 kg, 600 mg/d; weight of >60 kg to 80 kg, 800 mg/d; weight of >80 kg, 1,000 mg/d.

Abbreviations: IQR, interquartile range; max, maximum; Peg-INF, pegylated interferon; SD, standard deviation

Weight-based dosing was as follows: weight of ≤60 kg, 600 mg/d; weight of >60 kg to 80 kg, 800 mg/d; weight of >80 kg, 1,000 mg/d.

Abbreviations: IQR, interquartile range; max, maximum; Peg-INF, pegylated interferon; SD, standard deviation

Fonatana et al (2001) 4
treatment with rasburicase and hemodialysis Discontinuati

Mean, 6.8/9.6

Week

Uric acid nephrolithiasis and hyperuricemia ascribed to ribavirin-induced hemolysis

Week

Mean, 6.8/9.6

Week

Fonatana et al (2001) 4
**Figure 1**

- **Uric acid**
- **Creatinine**

Diagram showing changes in uric acid and creatinine levels over time with ribavirin and rasburicase interventions.